Genmab A (GMAB) Short-term Investments (2018 - 2025)

Genmab A (GMAB) has reported Short-term Investments for 8 consecutive years, with $268.4 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Short-term Investments rose 524.28% year-over-year to $268.4 million; the trailing twelve-month figure through Sep 2025 stood at $268.4 million (up 524.28% YoY), and the FY2025 full-year result was $1.6 billion, up 1136.15% from the prior year.
• Short-term Investments slipped to $268.4 million in Q3 2025 per GMAB's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.9 billion in Q1 2021 and bottomed at $2.0 million in Q2 2024.
• Historically, Short-term Investments has averaged $938.6 million across 5 years, with a median of $1.2 billion in 2021.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments sank 99.85% in 2024, then jumped 80050.0% in 2025.
• Over 5 years, Short-term Investments stood at $1.2 billion in 2021, then plunged by 95.27% to $55.4 million in 2022, then soared by 2148.67% to $1.2 billion in 2023, then retreated by 16.08% to $1.0 billion in 2024, then tumbled by 74.34% to $268.4 million in 2025.
• According to Business Quant data, Short-term Investments over the past three periods registered $268.4 million, $1.6 billion, and $80.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.